**KHIDI-KASBP Regulatory Affair Workshop Draft Agenda**

**Seoul, Korea**

**August 2019 (TBD)**

|  |  |  |  |
| --- | --- | --- | --- |
| Time | Speaker | Topic  | Discussion Description |
| 9 am |  | FDA overview  | Overview of overall FDA structure. Review of a review division as an example. Typical FDA team members for assigned programs. |
| 10 am |  | eCTD submission | The format requirements for an actual submission to FDA; specifications and structure. |
| 11 am |  | networking | Attendees should meet each other in a networking session.  |
| Noon | All  | lunch | Sustenance break. |
| 1 pm  |  | preIND/IND success | The components that are required for a successful preIND/IND will be discussed.For example: - strategy / goals- timelines / planning - team roles and meeting practice - medical writer input to documents and briefing package - maintenance of the IND |
| 2 pm  |  | preIND “how to” including content | A to Z on what and how to request and complete a preIND meeting.  |
| 3 pm  |  | IND overview and M1, M2, M5 | Overall review of an IND.  |
| 4 pm  |  | M3 CMC detailed content review | CMC content |
| 5 pm  |  | M4 Pharm/Tox detailed content review  | Nonclinical content |
| 6 pm  |  |  | M1 = administrative documents such as forms, investigator’s brochure, labeling M2 = summary documentsM5 = clinical protocol (s) |
| 6-pm |  | Q&A |  |

**Speakers (Preliminary):**

Regulatory Affair: Sandy Suh, Exeltis R&D, Head - Regulatory Affairs

Regulatory Affair: John Kim, Pierre Fabre, Vice President - QA and Regulatory Affairs

M3 CMC: Young Chun Jung, Akebia Therapeutics, Director – Technical Operation

M4 Pharm/Tox: Sean Kim, Blueprint Medicines, Senior Director -Non-clinical Development